US 12,268,663 B2
Method for treating pruritus
John M. Yanni, Burleson, TX (US); and Eric C. Carlson, Burleson, TX (US)
Assigned to PRUVYC PHARMA, LLC, Cary, NC (US)
Filed by Pruvyc Pharma, LLC, Cary, NC (US)
Filed on Sep. 9, 2021, as Appl. No. 17/470,243.
Claims priority of provisional application 63/087,212, filed on Oct. 3, 2020.
Prior Publication US 2023/0085380 A1, Mar. 16, 2023
Prior Publication US 2023/0210809 A9, Jul. 6, 2023
Int. Cl. A61K 31/335 (2006.01); A61K 9/00 (2006.01); A61K 9/06 (2006.01); A61K 47/02 (2006.01); A61K 47/06 (2006.01); A61K 47/08 (2006.01); A61K 47/10 (2017.01); A61K 47/14 (2017.01); A61K 47/18 (2017.01); A61K 47/24 (2006.01); A61K 47/32 (2006.01); A61K 47/44 (2017.01)
CPC A61K 31/335 (2013.01) [A61K 9/0014 (2013.01); A61K 9/06 (2013.01); A61K 47/02 (2013.01); A61K 47/06 (2013.01); A61K 47/08 (2013.01); A61K 47/10 (2013.01); A61K 47/14 (2013.01); A61K 47/183 (2013.01); A61K 47/24 (2013.01); A61K 47/32 (2013.01); A61K 47/44 (2013.01)] 13 Claims
 
1. A method of acutely treating dermal pruritis in a human or animal consisting of topically administering to the skin a composition comprising 0.1 to 1% (w/w) olopatadine, wherein the dermal pruritis is caused by an insect bite, a dryness of the epidermis, a healing wound, an infection, a mechanical irritation, a burn, a synthetic chemical exposure, or a natural chemical exposure.